So, what to make of that. Wainwright might be on the high side...

So, what to make of that. Wainwright might be on the high side (a tad) - it's higher than it was pre the 210 "failure". Maybe $0.32 is about right under the current circumstances. Maybe it is a bit low if 210 can be resurrected following the review of the trial data.

But, it is quite speculative. All of the models have big assumptions in them (as they must). I think it is worth reading the reports and looking carefully at the assumptions. In most cases, I dial the assumptions back. That is my conservative approach. How far I dial them back is a fair bit of gut feel. GLTA